Assessing live microbial therapeutic transmission
The development of fecal microbiota transplantation and defined live biotherapeutic products for the treatment of human disease has been an empirically driven process yielding a notable success of approved drugs for the treatment of recurrent Clostridioides difficile infection. Assessing the potenti...
Saved in:
Main Author: | Jeremiah J. Faith |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Gut Microbes |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2024.2447836 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Transplantation of fecal microbiota from low to high residual feed intake chickens: Impacts on RFI, microbial community and metabolites profiles
by: Chunlin Xie, et al.
Published: (2025-01-01) -
Nutritional optimization of fecal microbiota transplantation in humans: a scoping review
by: Levi M Teigen, et al.
Published: (2025-12-01) -
The Relationship Between the Modulation of Intestinal Microbiota and the Response to Immunotherapy in Patients with Cancer
by: Laura Radoš, et al.
Published: (2025-01-01) -
Fecal Microbiota Transplantation: A Systematic Review of Therapeutic Potential, Preparation Techniques, and Delivery Methods Across Medical Conditions
by: Syamand Ahmed Qadir, et al.
Published: (2024-11-01) -
Fecal microbiome change in patients with ulcerative colitis after fecal microbiota transplantation
by: A. Y. Tikunov, et al.
Published: (2020-04-01)